NCT02279953View on ClinicalTrials.gov

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Major Depressive Disorder
Interventions
DRUG

Vortioxetine 10-20 mg

DRUG

Placebo

DRUG

SSRI

escitalopram, citalopram or sertraline

Trial Locations (17)

Unknown

EE001, Tallinn

EE002, Tallinn

FI002, Helsinki

FI003, Helsinki

FI005, Helsinki

FI001, Kuopio

FI006, Kupio

FI004, Turku

DE002, Berlin

DE001, Bielefeld

DE005, Bochum

DE003, Frankfurt

DE004, Mittweida

RS002, Belgrade

RS001, Kragujevac

SK003, Levice

SK002, Rimavská Sobota

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02279953 - Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder | Biotech Hunter | Biotech Hunter